H

ow bullish are health care investors about the future success of Incyte’s (INCY) IDO inhibitor epacadostat? Depending on who you ask, the cancer immunotherapy accounts for $10 billion to $12 billion of Incyte’s current $27 billion market value. That’s a huge bet on a single drug not yet approved.

If epacadostat were a stand-alone company, it would be worth the same as Kite Pharma (KITE), which is being acquired by Gilead Sciences (GILD) for just under $12 billion. Investors value the drug more than Jazz Pharmaceuticals (JAZZ), Seattle Genetics (SGEN), and Exelixis (EXEL), all of which have approved, successfully marketed products.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.